- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Sonus expands relationship with Abbott
Ultrasound contrast developer Sonus Pharmaceuticals of Bothell,WA, has extended its relationship with Abbott Laboratories toinclude the clinical development and marketing of Sonus' EchoGenagent in the U.S.Last week's deal builds on a relationship between
Ultrasound contrast developer Sonus Pharmaceuticals of Bothell,WA, has extended its relationship with Abbott Laboratories toinclude the clinical development and marketing of Sonus' EchoGenagent in the U.S.
Last week's deal builds on a relationship between Sonus and Abbottthat began in 1993 for manufacturing of EchoGen. Under the newagreement, Abbott will pay Sonus $31 million in up-front, clinicalsupport, and milestone payments in return for U.S. marketing rights.In addition, Abbott paid $4 million for warrants to acquire 500,000shares of Sonus stock, equal to about 6% of shares outstanding.Sonus will receive 47% of net EchoGen revenues in the U.S. andthe company retains some co-promotion rights to EchoGen in theU.S.
EchoGen has completed phase III radiology and cardiology trialsin the U.S. and Sonus expects to file a new drug application forthe agent this year, followed by a filing with the European MedicinesEvaluation Agency. French contrast firm Guerbet has rights toEchoGen in Europe, while Daiichi Pharmaceutical retains marketingrights for the product in the Pacific Rim.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
